Ocugen (OCGN) said Monday that the European Medicines Agency's Committee for Advanced Therapies had issued a positive opinion for OCU400's classification as advanced therapy medicinal product.
OCU400, Ocugen's gene therapy candidate to treat retinitis pigmentosa, is being evaluated in an ongoing phase 3 trial, the company said.
Ocugen said it intends to file an application for marketing authorization in the EU next year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。